Hepatocellular carcinoma is one of the most common malignant tumors in China, and its annual incidence rate ranks third in malignant tumors and second in mortality rate according to the estimation of the results of population survey in recent years. As hepatocellular carcinoma develops insidiously and progresses rapidly, it is mostly in the middle and late stages when clinical symptoms appear, and the opportunity of surgical resection is lost. For advanced stage patients, the efficacy is very poor due to many problems such as liver insufficiency and systemic metastasis of tumor, and the 5-year survival rate is less than 5%. And systemic chemotherapy is almost ineffective for liver cancer, and no new breakthrough has been seen. In recent years, targeted therapy has made a breakthrough in the treatment of malignant tumors, which has opened up a new field and provided new thinking for the treatment of malignant tumors, resulting in new trends in the research of many advanced malignant tumors, and also giving new hope to patients and their families. It can also be said that the treatment of advanced hepatocellular carcinoma, which has been wandering in the darkness, has seen a ray of hope. Targeted hepatocellular carcinoma treatment represented by sorafenib has gained international recognition and has been approved by governments in Europe, America and Asian countries, including China, for the treatment of intermediate and advanced hepatocellular carcinoma; it has also been confirmed through numerous clinical studies that the drug can prolong patients’ lives. Due to the high price of this drug, patients who are eager for life have really experienced the true meaning of “an inch of money cannot buy an inch of time”, and also made people really think about the difference between “money is not spent when the person is gone” and “the person is still alive when the money is spent”. It also makes people really think about how to choose between “the person is alive even after the money is spent” and “the person is dead even after the money is spent”. In any case, the introduction of targeted therapy for liver cancer has brought a blessing to many patients with mid- to late-stage liver cancer in China, bringing them back from the dead, as well as the first light of research in related fields. It is believed that it is only a matter of time before the price of drugs decreases and more effective drugs are developed, and there is hope if you live!